Moderna, Inc. Common Stock (MRNA)
Health Care – BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
- CEO
- Stéphane Bancel
- Headquarters
- United States
- Employees
- 4,700
- Market Cap
- $57.5B
About Moderna, Inc. Common Stock
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
SentiSense also tracks daily options readings for Moderna, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Moderna, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.